Skip to main content
. 2020 Aug 27;2(3):zcaa017. doi: 10.1093/narcan/zcaa017

Figure 2.

Figure 2.

Mutation signatures enriched in BRCA-mutated tumors expressing wild-type or mutant form of POLQ. Proportions of 65 SBS (A) or 17 ID (B) signatures are determined according to POLQ mRNA expression level (high: top 33rd percentile; low: bottom 33rd percentile) and POLQ mutation status in BRCA-mutated cancers. The SBS and ID signature enrichment was detected only in POLQ WT/High but not in WT/Low, MT/High, MT/Low.